CureVac NV Ownership
| 5CV Stock | EUR 2.49 0.09 3.75% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CureVac |
CureVac Stock Ownership Analysis
About 46.0% of the company shares are owned by insiders or employees . The book value of CureVac NV was presently reported as 3.29. The company recorded a loss per share of 0.63. CureVac NV had not issued any dividends in recent years. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. CUREVAC N operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 455 people. For more info on CureVac NV please contact LLM LLM at 49 7071 9883 0 or go to https://www.curevac.com.CureVac NV Outstanding Bonds
CureVac NV issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CureVac NV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CureVac bonds can be classified according to their maturity, which is the date when CureVac NV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in CureVac Stock
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in CureVac Stock please use our How to Invest in CureVac NV guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.